Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Short term Debt (2019 - 2025)

OptimizeRx (OPRX) has disclosed Short term Debt for 5 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • Quarterly Short term Debt rose 112.75% to $4.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Dec 2025, up 112.75% year-over-year, with the annual reading at $4.3 million for FY2025, 112.75% up from the prior year.
  • Short term Debt hit $4.3 million in Q4 2025 for OptimizeRx, up from $3.3 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $4.3 million in Q4 2025 to a low of $2.0 million in Q4 2023.
  • Historically, Short term Debt has averaged $3.0 million across 3 years, with a median of $3.3 million in 2024.
  • Biggest YoY gain for Short term Debt was 112.75% in 2025; the steepest drop was 5.71% in 2025.
  • Year by year, Short term Debt stood at $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then skyrocketed by 112.75% to $4.3 million in 2025.
  • Business Quant data shows Short term Debt for OPRX at $4.3 million in Q4 2025, $3.3 million in Q3 2025, and $3.3 million in Q2 2025.